Why argenx SE’s (ARGX) Stock Is Up 14.33%
As of Monday, August 17, argenx SE’s ARGX share price has surged by 14.33%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Commentary & Analysis
Why argenx SE’s (ARGX) Stock Is Up 16.03%
As of Monday, August 17, argenx SE’s ARGX share price has surged by 16.03%, which has investors questioning if this is right time to sell.Tudor Pop
Is argenx SE (ARGX) Overvalued?
We dive into why argenx SE (ARGX) could be considered overvalued on 2026-07-16, based on AAII’s Value Score and Grade.Tudor Pop
Why argenx SE’s (ARGX) Stock Is Up 5.90%
As of Friday, June 05, argenx SE’s ARGX share price has surged by 5.90%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why argenx SE’s (ARGX) Stock Is Down 5.01%
As of Monday, January 05, argenx SE’s ARGX share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ARGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $64,746.9 | $286.3 | 95% |
|
| Shares Out (Mil) | 64.5 | 54.2 | 53% |
|
| Institutional Ownership | 99.8% | 92.8% | 94% |
|
| Float (Mil) | 62.4 | 39.7 | 52% |
|
| Beta | -0.02 | 0.94 | 5% |
|
| Avg Daily Volume (000s) | 338 | 534 | 52% |
|
| Price Change (52-week) |
58.1% | 58.7% | 82% |
|
| Growth | ARGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 132.8% | 13.6% | 99% |
|
| Net Income (5yr) | 32.8% | (10.1%) | 87% |
|
| EPS (5yr) | 28.2% | 16.0% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 11.8% | (15.6%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 17 | 16 | |
| Current EPS | $7.522 | $29.041 | $39.196 | |
| Month Ago EPS | $7.623 | $26.858 | $37.185 | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $7.195 | $27.587 | $36.959 | |
| Year/Year Chg | 3.0% | 48.4% | 149.4% | |
| Financials | ARGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5,316 | $37 | 76% |
|
| Net Income (TTM) (Mil) | $1,715 | ($43) | 91% |
|
| EPS (TTM) | $27.720 | ($1.400) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($31) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $36 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $51,535 | $160 | 92% |
|
| Valuation | ARGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.72 | 2.77 | 86% |
|
| P/E | 39.6 | 19.1 | 78% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.4 | 1.0 | 57% |
|
| Ratios | ARGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.1% | 64.2% | 72% |
|
| Net Margin | 32.3% | (75.9%) | 90% |
|
| ROA | 23.1% | (47.3%) | 97% |
|
| ROE | 27.1% | (55.0%) | 86% |
|
| Liabilities to Assets | 16.1% | 29.6% | 10% |
|
| F-Score | 5 | 2 | 50% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.2% |
| +/- S&P 500: | +6.7 |
